Dr. Louise Provencher is a surgeon-oncologist at the CHU de Québec-Laval University. She is also a clinical researcher at the Research Center of the CHU de Québec-Laval University, and clinical professor at the Laval University School of Medicine. Dr. Provencher is part of the research group of the Centre des Maladies du Sein of CHU de Québec-Laval University.

Dr. Provencher is a scientific committee member at the McPeak-Sirois research group and the CHU de Quebec leader for the National Surgical Adjuvant Breast and Bowel Project.

Using structured breast cancer data

The Centre des Maladies du Sein research team has a comprehensive database of all cancers diagnosed since 1974; more than 12,000 patients are listed. A database of biopsy data from 1999 is also available; data on more than 34,000 biopsies are listed. These databases allow quality publications that modify the management and follow-up of cancers and benign breast diseases.

Offer innovative treatments

The Centre des Maladies du Sein of CHU de Québec-Laval University research group is one of the largest in Canada offering innovative treatments for breast cancer. More than 50 clinical trials are active at all times and are offered to patients who consult at the clinic or are referred by clinics/hospitals in the area. These clinical trials provide access to innovative experimental medications and develop the expertise of our world-renowned oncologists.

Supporting quality of life

The Centre des Maladies du Sein of CHU de Québec-University research group is a pioneer in quality of life studies in breast cancer, from total mastectomy to partial mastectomy, to the use of the cooling cap to counteract hair loss, promoting physical activity to improve survivorship, including optimal preservation of the axillary lymph nodes. The research group is at the forefront of studies promoting quality of life despite the adverse effects of the disease on an individual’s life.

Hôpital Saint-Sacrement
1050, chemin Sainte-Foy
Centre des maladies du sein Deschênes-Fabia
Québec, Québec
Canada G1S 4L8
84 entries « 1 of 9 »

Geyer CE, Bandos H, Rastogi P, Jacobs SA, Robidoux A, Fehrenbacher L, Ward PJ, Polikoff J, Brufsky AM, Provencher L, Paterson AHG, Hamm JT, Carolla RL, Baez-Diaz L, Julian TB, Swain SM, Mamounas EP, Wolmark N

Correction to: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

Journal Article

Breast Cancer Res Treat, 193 (3), 2022.

| Links:

Geyer CE, Bandos H, Rastogi P, Jacobs SA, Robidoux A, Fehrenbacher L, Ward PJ, Polikoff J, Brufsky AM, Provencher L, Paterson AHG, Hamm JT, Carolla RL, Baez-Diaz L, Julian TB, Swain SM, Mamounas EP, Wolmark N

Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology)

Journal Article

Breast Cancer Res Treat, 193 (3), 2022.

Abstract | Links:

Gagné M, Lauzier S, Lemay M, Loiselle CG, Provencher L, Simard C, Guillaumie L

Women with breast cancer's perceptions of nurse-led telephone-based motivational interviewing consultations to enhance adherence to adjuvant endocrine therapy: a qualitative study

Journal Article

Support Care Cancer, 30 (6), 2022.

Abstract | Links:

Giguère GB, Poirier B, Provencher L, Boudreau D, Leblanc D, Poirier É, Hogue JC, Morin C, Desbiens C

ASO Visual Abstract: Do Preoperative Prophylactic Antibiotics Reduce Surgical-Site Infection After Wire-Localized Lumpectomy? A Single-Blind Randomized Clinical Trial

Journal Article

Ann Surg Oncol, 29 (4), 2022.

| Links:

Ganz PA, Bandos H, Geyer CE, Robidoux A, Paterson AHG, Polikoff J, Baez-Diaz L, Brufsky AM, Fehrenbacher L, Parsons AW, Ward PJ, Provencher L, Hamm JT, Stella PJ, Carolla RL, Margolese RG, Shibata HR, Perez EA, Wolmark N

Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer

Journal Article

Breast Cancer Res Treat, 192 (1), 2022.

Abstract | Links:

Giguère GB, Poirier B, Provencher L, Boudreau D, Leblanc D, Poirier É, Hogue JC, Morin C, Desbiens C

Do Preoperative Prophylactic Antibiotics Reduce Surgical Site Infection Following Wire-Localized Lumpectomy? A Single-Blind Randomized Clinical Trial

Journal Article

Ann Surg Oncol, 29 (4), 2022.

Abstract | Links:

Gagnet S, Diorio C, Provencher L, Mbuya-Bienge C, Lapointe J, Morin C, Lemieux J, Nabi H

Identifying Clinicopathological Factors Associated with Oncotype DX 21-Gene Recurrence Score: A Real-World Retrospective Cohort Study of Breast Cancer Patients in Quebec City, Canada

Journal Article

J Pers Med, 11 (9), 2021.

Abstract | Links:

Wardley A, Cortes J, Provencher L, Miller K, Chien AJ, Rugo HS, Steinberg J, Sugg J, Tudor IC, Huizing M, Young R, Abramson V, Bose R, Hart L, Chan S, Cameron D, Wright GS, Graas MP, Neven P, Rocca A, Russo S, Krop IE

The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer

Journal Article

Breast Cancer Res Treat, 187 (1), 2021.

Abstract | Links:

Ennour-Idrissi K, Dragic D, Issa E, Michaud A, Chang SL, Provencher L, Durocher F, Diorio C

DNA Methylation and Breast Cancer Risk: An Epigenome-Wide Study of Normal Breast Tissue and Blood

Journal Article

Cancers (Basel), 12 (11), 2020.

Abstract | Links:

Labonte M, Guillaumie L, Dionne A, Dorval M, Nabi H, Lemieux J, Provencher L, Lauzier S

Development of a community pharmacy-based intervention to enhance adherence to adjuvant endocrine therapy among breast cancer survivors guided by the Intervention Mapping approach

Journal Article

Res Social Adm Pharm, 16 (12), 2020.

Abstract | Links:

84 entries « 1 of 9 »
Signaler des ajouts ou des modifications

Active projects

  • A phase II randomized study evaluating the biological and clinical effects of the combination of palbociclib with letrozole as neoadjuvant therapy in women with estrogen receptor-positive primary breast cancer, from 2016-03-30 to 2025-12-25
  • Breast adipocyte hypertrophy: a novel biomarker to predict breast cancer survival, from 2022-01-01 to 2023-03-31
  • Effect of environmental contaminants and methylome of breast adipose tissue on aromatase inhibitor efficacy in breast cancer, from 2016-07-01 to 2024-09-30
  • NSABP Breast Cancer Treatment Protocols, from 1997-02-01 to 2025-12-25
  • Omega-3 fatty acids in the prevention of breast cancer: role of obesity-related markers in breast tissues, from 2018-10-01 to 2026-09-30
  • Towards better outcomes for young women with breast cancer : A pan-canadian collaborative - Reducing the bUrden of Breast cancer in Young women (RUBY), from 2016-03-10 to 2025-12-25

Recently finished projects

  • Excellence in advanced cancer clinical trials initiative (the ExACCT Initiavive) , from 2017-01-18 to 2021-03-31
  • Mise à jour des connaissances en cancer du sein, from 2018-01-24 to 2021-03-31
  • Pilot study of a community pharmacy-based program to enhance adherence to adjuvant endocrine therapy among breast, from 2019-10-01 to 2022-02-28
  • Utilisation de l'intelligence artificielle (IA) afin de prédire les résultats de biopsies faites pour les mammographies anormales avec comme but ultime de réduire le nombre de biopsies , from 2019-12-09 to 2021-12-08
  • Utilisation de l'intelligence artificielle afin de maintenir automatiquement le registre national de suivi en cancer du sein et du projet de recherche en cancer du sein associé, from 2019-01-01 to 2021-12-31
Data provided by the Université Laval research projects registery